The late sodium current inhibitor ranolazine reverses the main electrophysiological and mechanical abnormalities of human hypertrophic cardiomyopathy (HCM) cardiomyocytes in vitro, suggesting potential clinical benefit. We aimed to assess the effect of ranolazine on functional capacity, symptomatic status, diastolic function, and arrhythmias in HCM.
H
ypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiomyopathy, affecting ≈1 in 500 individuals worldwide.
1-3 Symptoms of heart failure and functional limitation are common in patients with HCM, including 10% to 15% developing severe congestive symptoms (New York Heart Association class III-IV) and ≈5% proceeding to end-stage disease and heart failure-related death. [4] [5] [6] The pathophysiology of symptoms and disease progression is complex and only partially understood although several interrelated conditions are known to impact the long-term clinical course, including diastolic dysfunction, dynamic left ventricular outflow obstruction, microvascular ischemia, and atrial fibrillation. [1] [2] [3] [4] 7, 8 Furthermore, patients with HCM are at increased risk of ventricular arrhythmias, representing the principal cause of sudden cardiac death.
1, 2, 8 To date, no available therapy has shown the potential to change the natural history and clinical course of HCM. 7, 9 Ranolazine is an inhibitor of the cardiac late sodium current (I NaL ). 10, 11 I NaL is enhanced under several pathological conditions, such as myocardial ischemia, heart failure, and cardiac hypertrophy. 12 An increase in I NaL causes sodium (Na + ) overload which, in turn, promotes an increased exchange of intracellular Na + for extracellular calcium (Ca 2+ ) causing Ca 2+ overload and prolongation of the action potential. 12 We have recently shown that ranolazine is capable of reversing several adverse pathophysiological features observed in isolated cardiomyocites from patients with HCM. 12 By blocking I Nal and reducing intracellular calcium overload, ranolazine has shown a beneficial effect on improved diastolic properties and arrhythmic propensity of the HCM myocardium. 12, 13 In the long term, the effect on calcium homeostasis is expected to downregulate specific signaling pathways involved in pathological cardiac remodeling, such as the calmodulin kinase-II cascade, inhibiting pathways leading to fibrosis. 14 In addition, ranolazine is well-known to relieve myocardial ischemia in patients with stable coronary artery disease 14, 15 and might thus prevent ischemia and its long-term consequences in HCM. 4, 16 Therefore, ranolazine seems to have an ideal profile for clinical use in patients with HCM because of a wide range of actions that may reduce acute symptoms, improve exercise tolerance and quality of life, and decrease arrhythmic propensity. 12, 13, 17 Based on this rationale, we conducted an international double-blind, placebo-controlled pilot study to assess the efficacy and safety of ranolazine in patients with symptomatic, 
PATIENTS AND METHODS

Study Design
Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to Dr Olivotto at olivottoi@aou-careggi.toscana.it. Formal authorization by the study sponsor will be required.
The aim of this randomized international multicenter, placebo-controlled, double-blind phase 2 pilot study was to demonstrate the efficacy of a 5-month treatment course with ranolazine on exercise capacity, diastolic function, and symptomatic status in patients with HCM. Patients were eligible if the following inclusion criteria were met: male or female patients aged >18 years fulfilling the conventional echocardiographic criteria for the diagnosis of HCM, with maximum left ventricular wall thickness ≥15 mm; exertional symptoms and functional limitation (because of angina or heart failure) New York Heart Association class II to III; peak oxygen consumption (VO 2 ) at screening evaluation <75% of that predicted based on age and sex (irrespective of whether the anaerobic threshold was crossed); presence of sinus rhythm; and absence of resting left ventricular outflow tract obstruction (ie, a peak resting gradient <30 mm Hg at echocardiography).
Exclusion criteria comprised any one of the following: Females of childbearing potential not using adequate contraceptive precautions or pregnant/lactating; known coronary artery disease; chronic obstructive airways disease; clinically relevant hematological or biochemical abnormality on routine screening, according to investigator's judgment; severe concurrent pathology, including terminal illness; dementia, psychosis,
WHAT IS NEW?
• The late sodium current inhibitor ranolazine exerts favorable in vitro effects on cardiomyocytes from patients with hypertrophic cardiomyopathy (HCM), suggesting potential clinical benefit. However, in this prospective randomized trial enrolling patients with nonobstructive HCM, ranolazine was not effective in improving exercise capacity for a 5-month treatment course. Plasma prohormone brain natriuretic peptide levels, diastolic function, and quality of life measures were also unaffected.
• The drug showed an excellent safety profile and was associated with reduced 24-hour burden of premature ventricular complexes.
WHAT ARE THE CLINICAL IMPLICATIONS?
• The results of the present trial do not support the use of ranolazine to improve functional capacity in patients with HCM.
• The drug can be safely used in patients with HCM according to the standard indications for which ranolazine was developed, that is, control of anginal symptoms. However, late sodium current inhibition does not seem to have a role in ameliorating congestive symptoms related to diastolic dysfunction in HCM.
or chronic abuse of drugs or psychoactive substances; severe renal impairment (glomerular filtration rate <29 mL/min or creatinine >2.5 mg/dL); moderate or severe hepatic impairment (serum glutamic oxaloacetic transaminase or serum glutamic pyruvic transaminase >2× or total serum bilirubin >1.5× normal upper limit); concomitant administration of potent CYP3A4 inhibitors, dronedarone, class Ia or class III antiarrhythmics other than amiodarone or other QT-prolonging drugs; potent CYP3A4 inducers; >1000 mg daily dose of metformin; >20 mg daily dose of simvastatin during the study; baseline QTc ≥500 ms, calculated using the standard Bazett formula. The study protocol and amendments, as well as the informed consent form, were reviewed and approved by the relevant national authority in each country and by the independent ethics committee at each participating center. The study was conducted in compliance with the provisions of the Declaration of Helsinki. All the patients provided written informed consent before enrollment.
End Points
Primary End Point
The study aimed to demonstrate the efficacy of ranolazine in improving exercise capacity assessed by peak oxygen consumption (peak VO 2 ) during cardiopulmonary exercise test. The primary end point was defined as the change in peak VO 2 compared with baseline after 5-month treatment with placebo or ranolazine at the maximal tolerated dose (500 or 750 or 1000 mg bid).
Secondary End Points
Effect of treatment on diastolic function (expressed as change in echocardiographic E/E′), symptomatic status (expressed as change in Minnesota Living With Heart Failure Questionnaire score), neurohormonal profile (expressed as change in prohormone brain natriuretic peptide [proBNP] levels), and 24-hour premature ventricular complex (PVC) burden were evaluated as secondary end-points. The assessment of safety by evaluation of adverse events, laboratory findings, and standard 12-lead ECG was also considered a secondary study objective.
Study Protocol
Patients who met the inclusion/exclusion criteria, after signing the informed consent, were invited to the screening visit (Figure 1 ), for collection of demographic data, medical history, physical examination, routine laboratory tests, resting ECG, cardiopulmonary exercise test, Minnesota Living With Heart Failure Questionnaire, 24-hour ECG Holter monitoring, E/E′ ratio, proBNP evaluation, and urine pregnancy test (if applicable). After randomized allocation to either ranolazine or placebo by a computer-generated 4-block randomization list, eligible patients then entered the titration phase.
Ranolazine or placebo was administered, on top of preexisting standard treatment for HCM, at the initial dose of 500 mg bid; after 7 days, the dose was up-titrated to 750 mg bid in all patients (visit 2, time −7 days), and further titration up to 1000 mg bid was performed after 7 days (visit 3, time 0; Figure 1 ). If up-titration to 750 or 1000 mg was not advisable/tolerated, patients continued at 500 or 750 mg, respectively, throughout the study. Duration of treatment was 5 months (Figure 1 ).
Cardiopulmonary Exercise Test
Peak VO 2 evaluation was performed at visits 1 (2 weeks before baseline), 4, and 6 (respectively 4 and 20 weeks post-baseline). Cardiopulmonary exercise test was performed on an electrically braked cycloergometer with progressively increasing work rates (25-watt workload increment every 2 minutes). Sites were instructed to perform cardiopulmonary exercise test at the same time of day, with background medications taken in the same doses and time intervals before each test. A 12-lead exercise ECG was recorded continuously during the test and after 5 minutes of recovery; arterial pressure measurements were obtained at the first and second minutes of each step using cuff sphygmomanometers. Breath-by-breath measurements of oxygen uptake, carbon dioxide production, and respiratory flow were performed. Oxygen, carbon dioxide, and flow sensors were calibrated immediately before each test. All tests were reviewed and analyzed in a core laboratory. Patients were stimulated to achieve their maximum predicted heart rate; reasons for test termination followed standard guidelines. 18 Peak VO 2 was as averaged during the last 30 seconds of exercise. The test score (the time taken on the test, in minutes) was converted to an estimated VO 2 maximum score (maximal oxygen consumption), expressed as mL of oxygen per kilogram of body weight per minute. 19 Patients were considered to have crossed the aerobic threshold past the intersection of a 2 line regression of the VCO 2 versus VO 2 (V-slope) graph, with a change of the slope from <1 to ≥1.
E/E′ Ratio and ProBNP Evaluation
E/E′ ratio measurements were performed using commercially available ultrasound systems incorporating tissue Doppler imaging capabilities at the lateral and septal mitral annulus at visits 1 (2 weeks before baseline), 4, and 6 (respectively 4 and 20 weeks post-baseline) to evaluate changes from baseline. A core echocardiographic laboratory performed central review and analyses of the following parameters: transmitral pulse wave Doppler E max velocity; tissue Doppler imaging mitral annulus septal (septal E′), and lateral velocity (lateral E′); septal and lateral E/E′ ratio. ProBNP was measured at visits 1 (2 weeks before baseline), 4, and 6 (respectively 4 and 20 weeks post-baseline), using equipment and laboratory kits locally available at each center.
Sample Size and Enrollment Considerations
This was a superiority study. The sample size calculation was based on the ANOVA model, but the statistical analysis was performed applying the ANCOVA model for the absence of data on the correlation between basal and end of study values of the primary variable studied. For the primary end point, based on a 2-sided test at 5% significance level, with a power of 90% and an SD of ±4 mL kg −1 min −1 , to detect a change of 3 mL kg −1 min −1 in peak VO 2 (starting from a basal value ≈20 mL kg −1 min −1 , ie, a 15% change), a minimum of 38 patients per group were required. Enrollment of 100 patients was planned to reach a minimum of 76 patients available for analysis. However, because of slow recruitment, enrollment finished early on June 30, 2014 when a total of 119 patients had been screened and 80 randomized. The decision to stop recruitment followed a triple blind interim analysis showing that 29% of all patients achieved an increment of least 15% in the primary end point (peak VO 2 ) after 5 months of treatment, confirming sample size calculation assumptions. Based on this analysis, it was determined that a minimum of 29 patients per group (58 patients in total) would be sufficient to stop the study. This criterion provided >80% power to show a significant effect if the VO 2 peak change because of ranolazine was ≥3 mL·kg −1 ·min −1 . Even assuming an unexpectedly high dropout or protocol violation rate (up to 25%), the total number of randomized patients (n=80) was expected to retain sufficient statistical power for the final analysis.
Statistical Methods
Baseline characteristics are summarized as number and percentage (%) or mean±SD. Changes in peak VO 2 between the 2 treatment groups were analyzed using a 2-way ANCOVA with treatment as factor and baseline value as covariate. The least squares means, adjusted for any covariates included in the ANCOVA model, was used. The ANCOVA analysis was performed using the SAS PROC MIXED procedure. PROC MIXED is a generalization of the general linear model procedure in the sense that PROC general linear model fits standard linear models and PROC MIXED fits the wider class of mixed linear models. The PROC MIXED is designed for mixed effects models. Changes from baseline in peak VO 2 were analyzed using a maximum likelihood-based mixed model with treatment and country as fixed factors, baseline value as covariate, and patient as random factor. The model does not include the treatment by country interaction. Null hypothesis (H 0 ) of no difference between ranolazine and placebo at 5 months was assessed using the appropriate contrast from the model. The same model was used for the other continuous variables (delta proBNP, E/E′ ratio, and quality of life scores). All analyses are based on the intention to treat population unless specified differently. For the longitudinal data, the last observation carried forward approach was used to replace the missing values with the last values observed before dropout. A significance level of 0.05 was considered for each test. SAS (version 9.2) was used for all analyses.
RESULTS
Study Population
Between July 2012 and June 2014, 119 patients were screened for inclusion in the study. Of these, 39 (33%) were screening failures, largely because of a peak VO 2
Figure 1. Study design.
Ranolazine or placebo was administered, on top of pre-existing standard treatment for hypertrophic cardiomyopathy, at the initial dose of 500 mg bid; after 7 d, if the drug/placebo was well tolerated, the dose was up-titrated to 750 mg bid in all patients (visit 2, time −7 d), and one further titration up to 1000 mg bid was performed after another 7 d (visit 3, time 0), if the drug/placebo was well tolerated. If the up-titration to 750 or 1000 mg was not advisable, patients continued at 500 or 750 mg, respectively, throughout the study. Duration of treatment was 5 mo. Cardiopulmonary exercise test and the other tests relevant to the study end points were repeated at weeks 4 and 20. Bid indicates bis in die.
exceeding 75% of that predicted for age and sex. Thus, 80 patients were randomized, 40 in the ranolazine group and 40 in the placebo group. Patient demographics were well balanced (Table 1) . Eleven patients (14%) discontinued treatment early, 5 in the ranolazine group (12%) because of withdrawal of consent (n=3) and lack of compliance with the study protocol (n=2); and 6 in the placebo group because of lack of compliance (n=5) or because lost to follow-up (n=1; Figure 2) . Mean duration of treatment was comparable in the 2 treatment groups (ranolazine: 142.3 days; placebo: 143.7 days). Noncompliance was reported in 4 patients, who received <80% of the expected amount of treatment. All patients were included in the safety analysis population and the intention to treat population; the per protocol population included 29 patients in the placebo and 31 in the ranolazine group.
Primary End Point
At baseline, peak VO 2 of patients receiving ranolazine and placebo were comparable (16.91±5.01 versus 17.23±4.80 mL/kg per minute, respectively; P=0.847). 
Secondary End Points
ProBNP showed a decrease at 5 months versus baseline in the ranolazine arm (change from baseline, expressed as geometric mean median: −3, interquartile range: [−107, 142 pg/mL]) compared with a small increase in the placebo group (change from baseline, expressed as geometric mean median: 78, interquartile range: [−71, 242] pg/mL); however, this trend was not significant (P=0.251; Table 2 ). Changes in E/E′ ratio (both septal and lateral) at 5 months were similar in the 2 treatment arms (Table 2) . Similarly, symptomatic status evaluation using the Minnesota Living With Heart Failure Questionnaire improved to a similar degree in ranolazine and placebo group (Table 2) .
QTc Variations and Arrhythmias
Mean QTc values were comparable between treatment groups, with no significant change throughout the study. Values at baseline and at 5 months were 437±28 and 432±32 ms, respectively (change −5 ms), in the placebo arm, versus 433±33 and 431±31 ms, respectively (change −2 ms), in the ranolazine arm (P>0.8 for both comparisons). The QTc change mean value is modeled and related to the cohort of subjects with the QTc available both at baseline and end of study visit (n=38).
The number of PVCs at baseline 24-hour Holter ECG was greater in the ranolazine arm as compared with placebo (2193±9034 versus 176±402, respectively). At 5 months, this number decreased to 380±1111 versus 105±221, respectively; absolute reduction in PVCs from baseline was −1813 (ie, −82%) in the ranolazine arm compared with −71 (−40%) in the placebo arm (P=0.237). Of note, 24 of 40 patients (61%) receiving ranolazine had a ≥50% reduction in PVCs compared with 13 of 40 on placebo (33%; P=0.042).
Safety
Treatment with ranolazine was safe and well tolerated. No deaths occurred during the study. A similar number of drug-related adverse events was reported in the ranolazine (16 events) and in the placebo group (15 events; Appendix II in the Data Supplement). In the ranolazine group, the most frequently reported events were constipation, vomiting, dizziness, and insomnia. Assessment of vital signs showed no difference between treatment groups in heart rate and systolic or diastolic blood pressure. Likewise, there were no relevant safety signals from the laboratory assessments.
DISCUSSION
In the present study, we could not demonstrate a benefit of ranolazine on functional capacity of symptomatic patients with nonobstructive HCM. Ranolazine proved safe and well tolerated in patients with HCM, consistent with its excellent safety record in a variety of cardiac conditions. 20, 21 In the primary effi- cacy analysis, however, changes in peak VO 2 at 5 months showed no difference between the ranolazine and placebo arms. Furthermore, no effect could be detected on quality of life and diastolic function, as assessed by Minnesota Living With Heart Failure Questionnaire and E/E′ ratio, respectively, and ProBNP levels were unaffected. Thus, despite promising preclinical evidence, late sodium current inhibition does not seem to improve congestive symptoms related to diastolic dysfunction in HCM. This disappointing result may reflect the complexity of HCM pathophysiology and the difficulty of translating advantageous effects at the cellular level 12, 13 into clinical benefit. For example, features such as diffuse myocardial fibrosismanifesting at the organ level 4, 5, 7 -may well be capable of overruling the cellular effects of ranolazine. Of note, we chose not to include obstructive patients in the present study because of concerns that the effect of afterload mismatch might override the myocardial features of HCM pathophysiology 22 and thus obscure the effects of ranolazine on functional capacity. However, because nonobstructive patients are often free of severe symptoms, 6 the study inclusion criteria may have skewed selection toward the most severe end of the spectrum, resulting in the enrollment of individuals less responsive to pharmacological treatment. 5, 6 A prior attempt to influence left ventricular hypertrophy and fibrosis with losartan, the INHERIT study (Inhibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Hypertrophy-A Randomised Intervention Trial With Losartan), has also failed, indicating that structural modifications of adult HCM phenotypes may be hard to achieve by pharmacological interventions. 23 Conversely, the recent RESET-HCM trial showed that moderate-intensity exercise training leads to significant increase in exercise capacity and PVC burden reduction in patients with HCM for just 16 weeks. 24 Thus, as the quest for the ideal drug capable of reverting HCM phenotypes continues, the less ambitious aim of inducing functional modifications by lifestyle interventions represents an important therapeutic opportunity.
Last but not least, the negative results of our trial may have a pharmacogenetic explanation, reflecting variability in late sodium current expression in HCM cardiomyocytes. 19, 25 As recently shown by our group, HCM pathophysiology is mutation rather than disease specific. In the study, the cardiomyocytes from 2 transgenic mouse lines with different cardiac troponin T mutations behaved differently in terms of electrophysiological remodeling. In the R92Q strain, I Nal was clearly overexpressed because of profound excitationcontraction coupling changes and ranolazine exerted a striking effect both in vitro (recapitulating those seen in human cardiomyocytes) and in vivo, including prevention of HCM phenotype development. 13 Conversely, the E163R strain, which did not overexpress I Nal , lacked in vitro response to ranolazine. 25 In similar instances, where HCM-associated mutations cause disease directly by mutation-driven abnormalities in myofilament function-and are not mediated by downstream excitation-contraction coupling abnormalities-molecules aimed at the primary sarcomere defect may prove effective. 26 Unfortunately, potential responders to I Nal inhibitors cannot be identified a priori in clinical practice. The only positive signal observed in our study was a reduction in ventricular arrhythmic burden in patients treated with ranolazine. At final evaluation, the proportion of patients with >50% reduction in PVCs on 24-hour Holter monitoring was double that of the placebo arm (61% versus 33%; P=0.042). Given the small sample size and the weak relation of PVC rate to hard clinical end points, this finding can only be considered as exploratory and hypothesis generating. Furthermore, the excess PVC burden present at baseline in the ranolazine arm warrants caution in its interpretation. However, this effect is consistent with the antiarrhythmic efficacy shown by ranolazine in patients with ischemic heart disease, both at the ventricular and supraventricular levels, 14, 27 and likely reflects its direct effect on the altered electrophysiological properties of isolated HCM cardiomyocytes, capable of reducing their arrhythmic propensity in vitro. 12 Ranolazine exerts antiarrhythmic effects on cardiac muscle because of multiple mechanisms. The inhibition of I NaL , a depolarizing current active during the plateau of the action potential, directly shortens action potential duration, leading to reduced occurrence of early afterdepolarizations. 28 Moreover, sustained reduction of intracellular Ca 2+ overload reduces spontaneous Ca 2+ leakage from the sarcoplasmic reticulum, determining lower occurrence of delayed after-depolarizations. 20 In human HCM cardiomyocytes, increased I NaL activity was associated with prolongation of action potentials and with the occurrence of early after-depolarizations and delayed after-depolarizations, both established markers of electric instability, which were successfully suppressed by ranolazine at therapeutic concentrations. 12 Although the present study was not powered to address an effect on life-threatening ventricular arrhythmias, and end point requiring considerably larger patient samples and follow-up duration, these effects suggest that impacting on cellular excitationcontraction coupling abnormalities may be beneficial in selected patients with HCM. 9, 12 In conclusion, ranolazine produced no benefit on exercise performance, diastolic function, biomarker levels, or quality of life in patients with nonobstructive HCM. The drug showed an excellent safety profile and was associated with reduced 24-hour PVC burden. Ranolazine can be used in patients with HCM according to the standard indications for which the drug was developed, that is, control of angina. However, late sodium current inhibition does not seem to have a role in ameliorating functional impairment related to diastolic dysfunction. Per protocol population: patients in the placebo group (n=29)+patients in the ranolazine group (n=31). IQR indicates interquartile range; ITT, intention to treat; LOCF, the last observations carried forward method used to replace missing data for any cause; MLWHFQ, Minnesota Living With Heart Failure Questionnaire; proBNP, prohormone brain natriuretic peptide; and PVCs, premature ventricular complexes.
*Wilcoxon rank-sum test P value. 
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